Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Prevention of Bone Loss After Acute SCI
NCT02325414Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Feb 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoporosis comparing Zol with Placebo (2 arms). Primary endpoints: Percent Change in Bone Mass Density in the Hip at 12 months and Percent Change of Bone Mass Density in the Femoral Neck at 12 months. Started Feb 2015; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02325414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325414.